Merck KGaA Resumes Stimuvax Studies in Lung Cancer
This article is for subscribers only.
Merck KGaA is resuming tests of its experimental cancer vaccine Stimuvax in lung tumor patients after getting clearance from U.S. regulators.
Authorities have lifted the hold on two of the three late-stage clinical trials of the therapy, a global lung cancer trial and a trial that focuses on lung tumor patients in Asia, the Darmstadt, Germany-based maker of drugs and chemicals said in an e-mailed statement today. Merck said it remains in talks with the Food and Drug Administration about the future of the third trial, in breast cancer patients.